Physician profile
Mark S Daunis
NPI 1215992813
$3,117.04
in general payments reported to CMS, 2019-2025
18 companies · $66.93 in 2025
The $66.93 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.07 · 2021: $821 · 2022: $824 · 2023: $986 · 2024: $400 · 2025: $66.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $659.01 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $651.84 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $447.10 | 2021-2025 | Trelegy Ellipta |
| Amgen INC. | $421.85 | 2021-2024 | Otezla, Repatha, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.77 | 2021-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $166.48 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Esperion Therapeutics, INC. | $106.81 | 2021-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $100.57 | 2022 | |
| Amarin Pharma, INC. | $64.68 | 2021 | |
| Tris Pharma INC | $47.89 | 2023-2024 | Dyanavel Xr |
| Exact Sciences Corporation | $44.02 | 2023 | Cologuard Collection Kit |
| Global Blood Therapeutics, INC. | $32.83 | 2021 | |
| Pfizer INC. | $32.39 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.07 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.77 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $17.95 | 2023 | Nexplanon |
| Teva Pharmaceuticals USA, INC. | $15.48 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Daunis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.